Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BW-00112 Injection in mixed dyslipidemia
CTR20241654Phase 2Active
- Sponsor
- Bolin Pharma
- Start
- Jun 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BW-00112 in combined dyslipidaemia, sponsored by Bolin Pharma. Started Jun 2024; status: active.
02
Drugs
BW-00112
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on CTR20241654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241654.